etkinlestirme kodunu girme Windows 10 Pro Lisans Key Satin Al bilgisayari tam surum yap insta takipci kazan instagram hesap satin al fotograf begen mailden dosya gondrmek resim upload fotografi yukle minecraft hileler Mini Racing Adventures hileli apk apk hileli nasil indirilir eski facebook hesabi Facebook 5 yildiz Derecelendirme Satin Al kapanan hesabi acma anlik muhabbet Canli Sex Hatti ucuz hatun numaralari seksi sohbet Yetiskin Sohbet Hatti canli kizlarla konus yetiskin videolari xnxx anal izle makine ile su kacagi tespiti kirmadan tamir yapilir
IngentaConnect A Review of Cilostazol, a Phosphodiesterase Inhibitor, and its Ro...
 

A Review of Cilostazol, a Phosphodiesterase Inhibitor, and its Role in Preventing Both Coronary and Peripheral Arterial Restenosis Following Endovascular Therapy

Authors: Dindyal, Shiva; Kyriakides, Constantinos

Source: Recent Patents on Cardiovascular Drug Discovery, Volume 4, Number 1, January 2009 , pp. 6-14(9)

Publisher: Bentham Science Publishers

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

Systemic vascular disease is the greatest cause of mortality in the western world. Treatment options have been preventative with medical therapy or curative with surgical bypass. Recently, there has been an increase in the use and popularity of minimally invasive endovascular techniques, particularly angioplasty and stent insertions. The short-term results of these techniques have been demonstrated to be superior in a number of studies when compared with conventional surgery, which itself carries high mortality and morbidity. The long-term outcomes of endovascular treatments have not been as impressive, due to vascular restenosis caused mainly by intimal hyperplasia. There have been a large number of studies and therapeutic trials to discover a solution to restenosis, but to date success has not been reached. Cilostazol is a phosphodiesterase inhibitor licensed for treating patients suffering from intermittent claudication. Recent clinical trials have shown the effects of cilostazol in also preventing coronary artery restenosis post-endovascular treatments. These results have recently been repeated for peripheral vascular stents. This review discusses the pharmacology of cilostazol, peripheral vascular disease, mechanisms of intimal hyperplasia causing vascular restenosis. We also discuss the use of cilostazol and other current patents of novel targets and therapeutics, for preventing restenosis of both coronary and peripheral arterial disease following endovascular therapies.

Keywords: Cilostazol; phosphodiesterase; inhibitor; endovascular; artery; coronary; peripheral; stent; restenosis

Document Type: Research article

DOI: 10.2174/157489009787260025

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$105.07 plus tax

Pressing the buy now button more than once may result in multiple purchases

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A